Chon-Seng Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chon-Seng Hong has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jhih-Yuan Shih
Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
2 shared publicationsTsung-Hsien Lin
Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2 shared publicationsWei-Chih Kan
Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan ROC
2 shared publications- Wei-Ting Chang
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2 shared publications Yu-Wen Lin
Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
2 shared publicationsZhih-Cherng Chen
Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan
2 shared publications
Latest Publications
- Open Access
- 3 October 2025
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (2) , 789
Correction: Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
- 3 October 2025
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (2) , 789
Open AccessCorrection: Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
- 19 April 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (7) , 2021-2032
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
Doxorubicin (Dox), an effective therapy in different types of cancer, is known to exhibit cardiotoxic effects. Despite previous studies indicating the benefits of dapagliflozin (DAPA) in patients experiencing heart failure, it remains uncertain whether DAPA exerts a protective effect on Dox-induced cardiac dysfunction. Signal transducer and activator of transcription 3 (STAT3) participates in various mechanisms of cardioprotection. Herein, we aimed to investigate the effects of DAPA on Dox-induced cardiotoxicity and the role of STAT3. Sprague–Dawley rats were pretreated with oral DAPA for 6 weeks followed by Dox for 4 weeks. Sequential echocardiography was applied to assess cardiac function. For in vitro analysis, cardiomyocytes were treated with 10 μM DAPA and subsequently exposed to 1 μM Dox. The expression of reactive oxygen species- and apoptosis-related proteins was measured. Using STAT3 siRNA, we further examined the effects of STAT3 effect on DAPA-associated protection against Dox-induced apoptosis. In rats treated with Dox, DAPA significantly reduced cardiac fibrosis and improved cardiac function and hemodynamics. Additionally, DAPA effectively inhibited Dox-induced apoptosis and reactive oxygen species (ROS) in cardiomyocytes. Mechanistically, we showed that DAPA decreased cardiac expression of Bax and cleaved caspase 3 but increased Bcl-2 expression. DAPA also significantly rescued Dox-suppressed STAT3 expression. Conversely, knocking down STAT3 in cardiomyocytes reversed the DAPA-related protective effects on Dox-induced cell apoptosis and ROS. Collectively, our findings indicate that DAPA could be useful for preventing Dox-induced cardiotoxicity by restoring STAT3.
- 19 April 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (7) , 2021-2032
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
Doxorubicin (Dox), an effective therapy in different types of cancer, is known to exhibit cardiotoxic effects. Despite previous studies indicating the benefits of dapagliflozin (DAPA) in patients experiencing heart failure, it remains uncertain whether DAPA exerts a protective effect on Dox-induced cardiac dysfunction. Signal transducer and activator of transcription 3 (STAT3) participates in various mechanisms of cardioprotection. Herein, we aimed to investigate the effects of DAPA on Dox-induced cardiotoxicity and the role of STAT3. Sprague–Dawley rats were pretreated with oral DAPA for 6 weeks followed by Dox for 4 weeks. Sequential echocardiography was applied to assess cardiac function. For in vitro analysis, cardiomyocytes were treated with 10 μM DAPA and subsequently exposed to 1 μM Dox. The expression of reactive oxygen species- and apoptosis-related proteins was measured. Using STAT3 siRNA, we further examined the effects of STAT3 effect on DAPA-associated protection against Dox-induced apoptosis. In rats treated with Dox, DAPA significantly reduced cardiac fibrosis and improved cardiac function and hemodynamics. Additionally, DAPA effectively inhibited Dox-induced apoptosis and reactive oxygen species (ROS) in cardiomyocytes. Mechanistically, we showed that DAPA decreased cardiac expression of Bax and cleaved caspase 3 but increased Bcl-2 expression. DAPA also significantly rescued Dox-suppressed STAT3 expression. Conversely, knocking down STAT3 in cardiomyocytes reversed the DAPA-related protective effects on Dox-induced cell apoptosis and ROS. Collectively, our findings indicate that DAPA could be useful for preventing Dox-induced cardiotoxicity by restoring STAT3.